Home » Posts tagged '2283422-04-6'
Tag Archives: 2283422-04-6
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....FOR BLOG HOME CLICK HEREFlag and hits
ORGANIC SPECTROSCOPY
SUBSCRIBE
Subscribe in a reader
Enter your email address:
Delivered by FeedBurner
Subscribe to New Drug Approvals by Email
Recent Comments
 | shivkr2 on SPSR Excellence Award 2025 – S… |
 | Bonkasaurus on Infigratinib phosphate |
 | PALOVAROTENE | ORGAN… on Palovarotene |
| Pfizer just purchase… on Temanogrel | |
| Pfizer To Cash In On… on Temanogrel |
Tebapivat
Tebapivat
CAS 2283422-04-6
WeightAverage: 392.44
Monoisotopic: 392.116778341
Chemical FormulaC18H16N8OS
10-[(6-aminopyridin-2-yl)methyl]-7-methyl-4-(1H-pyrazol-5-ylmethyl)-3-thia-5,7,10,11-tetrazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),4,11-tetraen-9-one
6-[(6-aminopyridin-2-yl)methyl]-4-methyl-2-[(1H-pyrazol-3-yl)methyl]-4,6-dihydro-5H-[1,3]thiazolo[5′,4′:4,5]pyrrolo[2,3-d]pyridazin-5-one
6-[(6-aminopyridin-2-yl)methyl]-4-methyl-2-[(1H-pyrazol-3-yl)methyl]-4,6-dihydro-5H-[1,3]thiazolo[5′,4′:4,5]pyrrolo[2,3-d]pyridazin-5-one
- AG946
- CS-0115951
- HY-135884
- ORG4KGP5ZS
- OriginatorAgios Pharmaceuticals
- ClassAntianaemics; Small molecules
- Mechanism of ActionPyruvate kinase stimulants
- Orphan Drug StatusYes – Myelodysplastic syndromes
- Phase IIAnaemia; Sickle cell anaemia
- 01 May 2025Phase-II clinical trials in Sickle cell anaemia in USA (PO) (NCT06924970)
- 01 May 2025Agios plans to initiate a phase II clinical trial for Sickle cell disease(PO) in mid-2025.
- 21 Feb 2025Agios Pharmaceuticals completes a phase I bioavailability trial (In volunteers) in USA (PO, capsule) (NCT06745271)
Tebapivat is under investigation in clinical trial NCT05490446 (A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-risk Myelodysplastic Syndromes (LR-MDS)).
Tebapivat is an orally available activator of the red cell isoform of pyruvate kinase (PK-R; PKR), with potential to improve hemolytic anemia and related-symptoms in patients with pyruvate kinase deficiency (PKD). Upon oral administration, tebapivat binds to and activates PKR, thereby enhancing glycolytic pathway activity in red blood cells (RBCs), improving adenosine triphosphate (ATP) levels and reducing 2,3-diphosphoglycerate (2,3-DPG) levels. This may result in increased oxygen affinity, improved RBC deformability, decreased sickle RBC hemolysis, increased hemoglobin (Hb) levels and improved RBC membrane function. Mutations in PKR cause deficiency in PKR which prevents adequate RBC glycolysis, leading to a build-up of the upstream glycolytic intermediate 2,3-DPG and deficiency in the PKR product ATP.
SCHEME
COUPLER
COUPLER
MAIN
PATENT
Agios Pharmaceuticals, Inc.
WO2019035864
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019035864&_cid=P22-MDGSEF-03229-1
Example 8A. Synthesis of 2-((1H-pyrazol-3-yl)methyl)-6-((6-aminopyridin-2-yl)methyl)- 4-methyl-4H-thiazolo[5′,4′:4,5]pyrrolo[2,3-d]pyridazin-5(6H)-one and 6-((6- aminopyridin-2-yl)methyl)-4-methyl-2-(1H-pyrazole-3-carbonyl)-4H- thiazolo[5′,4′:4,5]pyrroIo[2,3-d]pyridazin-5(6H)-one
Step F. Synthesis of 6-((6-aminopyridin-2-yl)methyl)-4-methyl-2-(1H-pyrazole-3- carbonyl)-4H-thiazolo[5′,4′:4,5]pyrrolo[2,3-d]pyridazin-5(6H)-one To a solution of tert- butyl (6-((4-methyl-5-oxo-2-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-3-carbonyl)- 4H-thiazolo[5′,4′:4,5]pyrrolo[2,3-d]pyridazin-6(5H)-yl)methyl)pyridin-2-yl)carbamate (20 mg, 0.03 mmol) in EtOH (1 mL) was added HCl (1 mL, 4 mol/L in dioxane). The mixture was stirred at 80 °C for lhr and cooled down. The precipitate was collected by filtration and neutralized with sat. NaHCO3, washed with water and dried to afford 5 mg of 6-((6- aminopyridin-2-yl)methyl)-4-methyl-2-(1H-pyrazole-3-carbonyl)-4H- thiazolo[5′,4′:4,5]pyrrolo[2,3-d]pyridazin-5(6H)-one. LC-MS (ESI): m/z 407 (M+H)+. 1H NMR (400 MHz, DMSO-d6) δ: 8.75 (s, 1H), 7.96 (s, 1H), 7.50 (s, 1H), 7.31-7.22 (m, 1H), 6.31 (d, 1H), 6.14 (d, 1H), 5.91 (s, 2H), 5.23 (s, 2H), 4.38 (s, 3H).
PATENT
WO2023091414
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2023091414&_cid=P22-MDGSRV-15431-1
PATENT
WO2019035863
WO2019035865
WO2019035864
AS ON JUNE2025 4.45 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT
join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE
join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com
……
/////////Tebapivat, 2283422-04-6, AG946, CS-0115951, HY-135884, AG 946, CS 0115951, HY 135884, ORG4KGP5ZS, AGIOS, Orphan Drug, PHASE 2,
New Drug Approvals 